试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-30
Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation
编号:NCT05039359登记状态:提前终止企业 / 申办者:InCarda Therapeutics, Inc.
药物 / 成分:FlecIH-103
登记的停止原因(原文):Limited efficacy upon blinded review
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-27
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
编号:NCT01500798登记状态:提前终止企业 / 申办者:Biogen
药物 / 成分:20 mg bardoxolone methyl、Placebo
登记的停止原因(原文):IDMC recommendation for safety concerns
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-27
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
编号:NCT01545141登记状态:提前终止企业 / 申办者:Roswell Park Cancer Institute
药物 / 成分:Chemokin Modulatory Regimen (5 MU/m2)、Chemokin Modulatory Regimen (10 MU/m2)、Chemokin Modulatory Regimen (20 MU/m2)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-27
Inflammation-Induced CNS Glutamate Changes in Depression
编号:NCT03004443登记状态:提前终止企业 / 申办者:Emory University
药物 / 成分:Infliximab、Placebo
登记的停止原因(原文):The study was suspended in March 2020 due to the COVID-19 pandemic and ultimately was terminated as it is not safe to test a potent anti-inflammatory drug with ongoing surges of COVID-19.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-27
Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
编号:NCT03636373登记状态:提前终止企业 / 申办者:Rutgers, The State University of New Jersey
药物 / 成分:Etanercept、Triamcinolone Acetonide
登记的停止原因(原文):The Sponsor has decided to stop funding this study due to lack of enrollment during COVID-19 pandemic and decreased interest in funding investigator initiated studies pertaining to the study drug
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-27
Intranasal Insulin in Frontotemporal Dementia (FTD)
编号:NCT04115384登记状态:提前终止企业 / 申办者:HealthPartners Institute
药物 / 成分:Novolin-R insulin
登记的停止原因(原文):COVID - unable to restart after restrictions were lifted
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-27
A Prospective Pilot Study to Assess the Efficacy of BOTOX-A in Patients With Low Anterior Resection Syndrome (LARS>20) and Refractory Medical Treatment After Rectal Resection
编号:NCT04991688登记状态:提前终止企业 / 申办者:University Hospital, Bordeaux
药物 / 成分:BOTOX-A
登记的停止原因(原文):Organizational difficulties
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
编号:NCT00496756登记状态:提前终止企业 / 申办者:University of Nebraska
药物 / 成分:Sorafenib
登记的停止原因(原文):Low accrual rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer
编号:NCT01041027登记状态:提前终止企业 / 申办者:Albert Einstein College of Medicine
药物 / 成分:Paclitaxel、Carboplatin、Internal Radiation Therapy、External Beam Radiation Therapy
登记的停止原因(原文):Due to slow accrual. Results from the PORTEC3 the study rendered the hypothesis no longer valid.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
编号:NCT01307956登记状态:提前终止企业 / 申办者:University of Nebraska
药物 / 成分:Fluorouracil、Laboratory Biomarker Analysis、Leucovorin Calcium、Oxaliplatin
登记的停止原因(原文):Drug manufacturer - Amgen requested study stop, per DSMB observation in POWER trial
查看官方原始记录 ↗